NCT03332576View on ClinicalTrials.gov

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 23, 2013

Primary Completion Date

September 8, 2016

Study Completion Date

September 9, 2019

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
BIOLOGICAL

DPX-Survivac

SubQ injection

BIOLOGICAL

DPX-Survivac(Aqueous)

SubQ injection

DRUG

Cyclophosphamide

PO BID

Trial Locations (3)

10028

Lenox Hill Hospital, New York

11501

Winthrop University Hospital, Mineola

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

ImmunoVaccine Technologies, Inc. (IMV Inc.)

INDUSTRY

NCT03332576 - Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | Biotech Hunter | Biotech Hunter